EMPOWERING MYELOMA ADVOCACY ACROSS EUROPE 
EMPOWERING MYELOMA ADVOCACY ACROSS EUROPE
Myeloma Patients Europe (MPE), in collaboration with the pharmaceutical company Amgen, launched a survey in 2019 for European myeloma patients to understand their treatment information needs.
Myeloma Patients Europe (MPE) held a webinar yesterday on ASH 2019 myeloma and AL amyloidosis highlights with the aim of reviewing the most recent myeloma findings presented at the annual meeting of the American Society of Hematology (ASH) that took place in Orlando, Florida, USA, in December 2019.
Myeloma Patients Europe will hold a webinar to review the most recent myeloma findings presented at the annual meeting of the American Society of Hematology (ASH) that took place in Orlando, Florida, USA, in December 2019.
Along with CAR-T cell treatment, bispecific antibodies has been one of the most important topics discussed at the American Society (ASH) Annual Meeting. This family of drugs has shown very promising results in early phases of clinical trials in heavily pre-treated myeloma patients. Dr Mohamad Mohty, Head of Haematology and and Celular Therapy Department, Saint-Antoine Hospital and University Pierre & Marie Curie, Paris, France, summarises for Myeloma Patients Europe (MPE) the most important updates…
Real World Evidence (RWE) is becoming more and more important not only for clinicians but also for scientific meetings such as the American Society of Hematology (ASH) Annual Meeting. Dr Faith Davies, NYU Langone Hospital, New York, USA, summarises in this video the most important updates regarding Real World Evidence in myeloma presented at ASH 2019.
Minimal Residual Disease (MRD) is one of the big topics in myeloma. Different techniques to measure MRD and new data about its role in predicting the risk of relapse are some of the topics discussed during the American Society of Hematology (ASH) Annual Meeting. In this video Dr Francesca Gay, University of Torino, Italy, explains for Myeloma Patients Europe (MPE) what was presented at ASH 2019 regarding MRD and the unanswered questions about its role…
More than 900 myeloma abstracts (posters and oral sessions) were presented in the largest world congress of hematology: the American Society of Hematology (ASH) Annual Meeting 2019 that was held from 7 to 10 December 2019 in Orlando, Florida, USA. Dr Faith Davies, NYU Langone Hospital, New York, USA, summarises in this video the most important myeloma updates presented at ASH 2019.
Dr Moshe Gatt, Hadassah Hebrew University Medical Center, Jerusalem (Israel) summarised for Myeloma Patients Europe (MPE) the main updates on AL amyloidosis presented at the American Society of Hematology (ASH) Annual Meeting held from 7 to 10 December 2019 in Orlando, Florida, USA.
ASH 2019, Orlando – New data presented by the HARMONY Alliance validate the current prognostic tool for Multiple Myeloma and have identified new parameters to improve the staging of the disease according to a press release publish by the Harmony Alliance. Myeloma Patients Europe (MPE) is part of the HARMONY Patient Cluster which is a unique group of 7 European Patient Umbrella Organizations working in the different areas of hematological diseases within the HARMONY…
